Background Critically ill patients with circulatory shock sometimes need rescue treatment with high doses of norepinephrine, a treatment that may be associated with a poor outcome because of excessive vasoconstriction. Objective To evaluate the outcome of treatment and its determinants in patients with circulatory shock who received high doses of norepinephrine in the intensive care unit and to identify indicators of futility for the treatment. Methods A retrospective study was done on 113 consecutive patients with circulatory shock who received 0.9 µg/kg per minute or greater of norepinephrine during at least 1 hour at any time in the intensive care unit. Data were extracted from the electronic patient data management system according to a predefined checklist. Results A total of 39 patients survived for 28 days after admission to the intensive care unit. The variables independently associated with 28-day mortality in multivariable models included low urine flow, high lactate levels, high organ failure score, high prothrombin time, and need for epinephrine cotreatment. The reason, dose, and duration of norepinephrine administration did not have prognostic significance. Scores greater than 40 on the Acute Physiology and Chronic Health Evaluation II, bicarbonate levels less than 9.0 mEq/L, or receipt of an epinephrine dose of 0.25 µg/kg per minute or greater were associated with 100% mortality. Conclusions Although the cause of shock and treatment with norepinephrine were not predictive of death when high doses of the drug were deemed necessary, rescue treatment with high-dose norepinephrine is futile in patients with severe disease and metabolic acidemia. (American Journal of Critical Care. 2013;22:22-32) HIGH-DOSE 1,2,5,6,9,10,13,15-18 A maximum tolerable dose has not been determined, even though excessive dosing is associated with a risk for extreme vasoconstriction, tissue hypoperfusion, and increased mortality. Consequently, many intensivists do not use doses greater than 100 µg/min or 1.2 µg/kg per minute. 2, 5, 8, [17] [18] [19] [20] [21] [22] [23] Indeed, use of high doses may be futile (ie, associated with 100% mortality), as reported previously, [17] [18] [19] 21 but currently the indicators for futility of this rescue treatment are unknown. They may vary according to underlying disease, causes of shock, and other factors. Abid et al 19 found that a score greater than 12 on the Sequential Organ Failure Assessment (SOFA) was associated with 100% mortality during (delayed) norepinephrine treatment for shock. Lactate levels may be confounded by the β-adrenergic effects of catecholamines, thereby potentially making the well-known prognostic value of the drugs in shock less helpful during treatment with norepinephrine, which has both α-and β-adrenergic properties. 1, 3, 5, 10, 13, 23, 24 The purpose of our study was to evaluate the outcome of ICU patients who received doses of norepinephrine of 0.9 µg/kg per minute or greater C ritically ill patients in the intensive care unit (ICU) may die of circulatory shock or its sequelae. The initial therapy for hypotension is fluid replacement followed by vasopressor or inotropic support, which depends on the type and severity of shock. However, despite recently published guidelines, large prospective comparisons, and meta-analyses, 1-11 the first-choice vasopressor is still controversial. At our institution, VU University Medical Centre, Amsterdam, the Netherlands, and at other facilities, norepinephrine is the vasopressor used first, regardless of the type and origin of shock, because equivalently effective doses of dopamine may be associated with more adverse effects and less beneficial outcomes. 8, 9, [12] [13] [14] [15] About the Authors Donna Döpp-Zemel is a registered intensive care nurse, Department of Nursing, and AB Johan Groeneveld is a professor, Department of Intensive Care, at VU University Medical Centre, Amsterdam, the Netherlands. 
Norepinephrine is usually administered as a continuous infusion at the bedside. The dose is based on the mean arterial blood pressure (MAP) judged to safeguard organ perfusion. Recommended initial doses are 8 to 12 µg/min or 0.10 to 0.15 µg/kg per minute. Doses up to 0.5 µg/kg per minute (range, 0.2-5.0 µg/kg per min at maximum) have been used in clinical studies. 1, 2, 5, 6, 9, 10, 13, [15] [16] [17] [18] A maximum tolerable dose has not been determined, even though excessive dosing is associated with a risk for extreme vasoconstriction, tissue hypoperfusion, and increased mortality. Consequently, many intensivists do not use doses greater than 100 µg/min or 1.2 µg/kg per minute. 2, 5, 8, [17] [18] [19] [20] [21] [22] [23] Indeed, use of high doses may be futile (ie, associated with 100% mortality), as reported previously, [17] [18] [19] 21 but currently the indicators for futility of this rescue treatment are unknown. They may vary according to underlying disease, causes of shock, and other factors. Abid et al 19 found that a score greater than 12 on the Sequential Organ Failure Assessment (SOFA) was associated with 100% mortality during (delayed) norepinephrine treatment for shock. Lactate levels may be confounded by the β-adrenergic effects of catecholamines, thereby potentially making the well-known prognostic value of the drugs in shock less helpful during treatment with norepinephrine, which has both α-and β-adrenergic properties. 1, 3, 5, 10, 13, 23, 24 The purpose of our study was to evaluate the outcome of ICU patients who received doses of norepinephrine of 0.9 µg/kg per minute or greater C ritically ill patients in the intensive care unit (ICU) may die of circulatory shock or its sequelae. The initial therapy for hypotension is fluid replacement followed by vasopressor or inotropic support, which depends on the type and severity of shock. However, despite recently published guidelines, large prospective comparisons, and meta-analyses, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] the first-choice vasopressor is still controversial. At our institution, VU University Medical Centre, Amsterdam, the Netherlands, and at other facilities, norepinephrine is the vasopressor used first, regardless of the type and origin of shock, because equivalently effective doses of dopamine may be associated with more adverse effects and less beneficial outcomes. medical noncoronary, scheduled surgery, and emergency surgery. Primary diagnoses at admission were classified as respiratory (including exacerbation of chronic obstructive pulmonary disease, pulmonary edema, pulmonary embolism, aspiration, pneumonia), cardiovascular (including rhythm disturbances, coronary artery disease, aortic aneurysm or dissection), after cardiac arrest, shock (including hypovolemic, cardiogenic, obstructive, and septic), trauma (including traumatic brain injury and multiple trauma), neurological (including stroke, intracranial hemorrhage and hematoma, subarachnoid hemorrhage), renal (including acute and chronic renal failure), metabolic (including uncontrolled diabetes mellitus), and gastrointestinal (including hollow viscus perforation, bowel ischemia, and peritonitis).
The type of shock at admission and at the time the highest norepinephrine dose was administered was classified as follows: no shock, hemorrhagic/ hypovolemic, cardiogenic, obstructive, septic, and unclassified (see following for definitions). Disease severity was assessed by using the score on the Acute Physiology and Chronic Health Evaluation (APACHE) II for worst values within 24 hours after admission. Scores on the SOFA 3, 5, 8, 10, 14, 16, 10, 20 with the most abnormal values within 24 hours were collected for each of the 6 organ systems at the time of admission and at the time of the high dose of norepinephrine. For single missing values, the closest value was carried backward or forward within 24 hours of time of admission or time of highest dose. Data collected for worst values within 24 hours at the 2 time points also included vital signs and hemodynamic, ventilatory, and biochemical variables. Vital signs and ventilatory and hemodynamic variables are summarized in the patient data management system on an hourly basis, so values at admission and at highest dose were easily retrieved. For biochemical variables, the worst value closest to time of admission and time of highest dose in a 24-hour window was retrieved. Urine flow on the day (or shorter part, if applicable) of the 2 time points was summarized as milliliters per kilogram per hour. If available, data were collected via pulmonary artery catheter at both time points, and maximum and minimum cardiac output and pulmonary capillary wedge pressure in 24-hour windows of time of admission and time of highest dose. Patients were followed up until death or ICU discharge, up to 28 days after admission.
Definitions
Circulatory In patients with persistent hypotension and organ hypoperfusion, as indicated by lactic acid emia, oliguria, and other signs, norepinephrine is the vasopressor used as a first-choice treatment. It is supplemented, if necessary, by epinephrine, dobutamine, or dopamine. 2, 4 Drugs are infused continuously at low starting doses (usually 0.1 µg/kg per minute for norepinephrine). Vasopressin and terlipressin are not used routinely. Rather, intravenous hydrocortisone is given for vasopressor-insensitive septic shock. The causes of shock are diagnosed and treated accordingly. Thrombolytic agents are administered when shock is judged to be caused by pulmonary embolism. Broad-spectrum antibiotics are administered in instances of septic shock. Care is provided by full-time intensivists, who supervise the ICU.
Study Protocol
Data were retrieved from the patient data management system for all consecutive patients who fulfilled the entry criteria within the appropriate time frame. Data were collected by using predefined case record forms and included patients' characteristics; comorbid conditions, classified according to the International Classification of Diseases Hypovolemic shock was defined as shock concurrent with loss of blood or plasma in the course of trauma, surgery, gastrointestinal bleeding, or burn wounds. Cardiogenic shock was defined as shock in the course of myocardial infarction (as indicated by abnormal electrocardiograms and results of biochemical tests) or congestive heart failure for other reasons. 15 Obstructive shock was defined as shock in the course of massive pulmonary embolism, pericardial tamponade, or tension pneumothorax. 12 Septic shock was defined as shock in the course of sepsis. Sepsis was defined as systemic inflammatory response syndrome with 2 or more of the following: abnormal body temperature (>38ºC or <36ºC), tachycardia (heart rate >90/min), tachypnea (respirations >20/min or PaCO 2 <32 mm Hg), need for mechanical ventilation, and abnormal white blood cell counts (<4000/µL or >12 000/µL), together with a clinically suspected or microbiologically proven source of infection. 26 Forms of shock without a clear single cause according to clinical findings were designated as unclassified. Acute renal failure was defined as the clinical need for renal replacement therapy as continuous venovenous hemofiltration. Vital outcomes were defined at day 28 after ICU admission as still hospitalized (either in the ICU or in the hospital), death, or discharge. Instances of treatment withdrawal were also documented.
Statistical Analysis
Because of predominantly nonnormal distributions, continuous variables were summarized as median and interquartile range. Vital outcome groups were compared by using the Mann-Whitney test for continuous variables and the Fisher exact test for categorical variables. When P < .05, variables were entered in a backward stepwise multivariable logistic regression analysis to find the smallest set of factors that best explained outcome, with elimination on the basis of the likelihood ratio. A Hosmer and Lemeshow goodness-of-fit test was performed, and odds ratios with 95% confidence intervals were computed. Multiple Cox proportional hazard regression was done in a similar fashion, to evaluate predictors of survival time (up to day 28). Hazard ratios and 95% confidence intervals are given. Receiver operating characteristic curves were made, and the area under the curve (AUC) was considered a measure of discriminating value. Finally, attempts were made to find statistically significant upper thresholds associated with 100% mortality to identify indicators of futility. P < .05 was considered significant.
Results
Between 2007 and 2009, a total of 113 consecutive patients fulfilled the inclusion criteria. Demographics and characteristics are summarized in Table 1 . A total of 39 patients (34%) survived 28 days after admission to the ICU. After day 28, a total of 2 patients died, 1 in the ICU and 1 in the hospital. Acute renal failure and high APACHE II scores were more frequent in nonsurvivors. Almost all patients received invasive mechanical ventilation, and the median length of ICU stay for the entire cohort was 7 (interquartile range, 16) days. Table 2 shows the collected clinical data at the time of admission and the time of the highest dose of norepinephrine. A total of 58 patients (51%) received the highest dose of norepinephrine at admission, so the values for time of highest dose partly overlap the values for time of admission. The maximum dose of norepinephrine administered in any patient was 2.91 µg/kg per minute. A dose of 2.22 µg/kg per minute or greater was associated with 100% mortality (n = 3; P = .55 vs lower dose). A long interval between the start of treatment with norepinephrine and the time of highest dose was associated with mortality. At time of admission and time of highest dose, the use of additional, high-dose epinephrine was also associated with mortality. Organ dysfunctions (Table 3) at time of admission and time of highest dose associated with mortality were metabolic deterioration (low pH, low bicarbonate level, high lactate level) and renal dysfunction (high serum creatinine level and low urine flow, for which futility thresholds could not be identified). Lower MAP and prolonged prothrombin time at time of highest dose were also associated with mortality. At both time of admission and time of highest dose, SOFA scores were higher in nonsurvivors than in survivors, but a threshold for futility could not be identified (Figure 1 ).
Multivariable Analysis
The variables retained in final models for prediction of mortality are depicted in 
25
Organ dysfunctions associated with mortality were metabolic deterioration and renal dysfunction.
Regardless of time, a low urine flow and high lactate level were associated with (relatively rapid) death.
(AUC, 0.70; P = .001) and high lactate levels at time of admission (AUC, 0.67; P = .004) and time of highest dose (AUC, 0.68; P = .002). The more complex APACHE II score at time of admission (AUC, 0.67; P = .003) and the SOFA score at time of admission (AUC, 0.72; P = .001) and time of highest dose (AUC, 0.71; P = .001) had similar predictive values. The even more complex multiple logistic regression models at time of admission and time of highest dose (Table 4) correctly classified outcome in 74% of cases and had the highest AUCs (0.76-0.82; P < .001). models were done for variables at time of admission and time of highest dose and at each time point are largely in line with each other. The findings indicate that regardless of time and model, low urine flow and high lactate levels were associated with (relatively rapid) death.
Predictive Values
The best predictive, single parameter for 28-day mortality was low urinary output at time of highest dose (AUC, 0.77; P < .001). Other good predictors were low bicarbonate level at time of admission 72 (15) 170 (11) 69 (18) 58 (78) 10 (14) 5 (7) 9 (12) 23 (31) 18 (24) 4 (5) 5 (7) 14 (19) 17 (23) 7 (9) 2 (3) 38 (51) 16 (22) 6 (8) 14 (19) 39 (53) 31 (42) 20 (27) 67 ( (28) 32 (43) 3 (6) 58 (78) 0 (0) 20 (51) 70 (15) 175 (14) 60 (25) 29 (74) 
Indicators of Futility
An APACHE II score greater than 40 was associated with 100% mortality (17 of 113 patients; P = .001). A concurrent dose at the time of admission (and/or time of highest dose of norepinephrine) of epinephrine (n = 37) of 0.25 µg/kg per minute or greater or of dobutamine (n = 28) of 12.0 µg/kg per minute or greater was associated with 100% mortality (n = 26; P < .001 and n = 5; P = .16, respectively). A bicarbonate level less than 9.0 mEq/L at the time of admission was associated with 100% mortality (n = 11; P = .02, Figure 2 ). For other variables and models of predictive value, statistically significant futility thresholds could not be identified.
Discussion
This retrospective study was done to evaluate the outcome of patients in the ICU who received highdose norepinephrine as a rescue treatment for shock. Although the outcome was grim (65% mortality), www.ajcconline.org (23) 5.5 (9.6) 5.5 (9.5) 7 (9) 7 (9) 35 (90) 39 (100) 3 (8) 3 (8) 3 (8) 1 (3) 4 (10) 2 (5) 2 (5) 3 (8) 12 (31) 11 (28) 13 (33) 21 (54) 36 (92) The mortality rate in our study, which includes mortality in the hospital until day 28, even after discharge from the ICU, is much higher than the mean ICU mortality rate in the Netherlands of about 11%. 27 Our patients had severe illnesses, and about 40% of nonsurvivors had septic shock. Other investigators 3, 5, 6, 8, 9, 13, 14, [16] [17] [18] [19] [21] [22] [23] have reported an ICU mortality rate of about 40% to 50% or greater associated survival is possible. Although neither dose and duration of norepinephrine treatment nor cause of shock contributed to prediction of death, the highdose treatment appeared futile (100% mortality) if associated with an APACHE II score greater than 40, a bicarbonate level less than 9.0 mEq/L, or an epinephrine dose of 0.25 µg/kg per minute or greater at the time of admission. 14 (4) 15 (4) 54 (12) 52 (13) 21 (28) 20 (27) 2.6 (2. (99) 120 (80) 113 (73) 14 (6) 15 (7) 25 ( 11 (5) 12 (6) 58 (16) 53 (15) 16 (41) 18 (46) 3.5 (2.6) 6.6 (4.1) 4.5 (3.1) 6.9 (4.5)
16 (12) 19 (7) 7.20 (0. (100) 112 (98) 111 (96) 11 (8) 14 (7) 5 ( with shock that required vasopressor treatment. Our finding agrees with the results of those reports. In our study, the norepinephrine dose itself (0.9-2.9 µg/kg per minute) was not a predictor of 28-day mortality. Few studies are available for comparison. Benbenishty et al 18 found that all patients who received greater than 3.8 µg/kg per minute of norepinephrine or greater than 9.6 µg/kg per minute of epinephrine died, but these doses were not reached in our cohort. In a study by Jenkins et al, 17 only 3% of patients who received doses of norepinephrine greater than 1.4 µg/kg per minute, similar to the doses we used, survived, and all of the patients who received more than 200 µg/min (2.8 µg/kg per minute) died. This outcome is worse than the outcome in our study. On the basis of some studies, 17 Figure 1 Sequential Organ Failure Assessment (SOFA) score and outcome on admission and when the highest dose of norepinephrine was administered. Outcome groups greatly differ in SOFA scores (P < .001), but there is no threshold above which mortality is 100%. The Hosmer-Lemeshow test confirmed the goodness of fit of the multivariable logistic regression models at admission (χ 2 = 13.8, df = 8, P = .09) and at the highest dose of norepinephrine (χ 2 = 8.7, df = 8, P = .36).
treatment in our study. Hence, high-dose norepinephrine treatment along with doses of epinephrine of 0.25 µg/kg per minute or greater may be futile, at least in our ICU. The association of epinephrine treatment with mortality otherwise agrees with some reports 14 but not with others, even though epinephrine may be associated with more adverse effects than is norepinephrine. 1, 3, 5, 10 We cannot compare different agents as rescue treatment for shock, because we almost exclusively use norepinephrine for that purpose in our ICU.
Arterial blood pressure itself was not independently associated with mortality, in disagreement with some studies 15, 16, 21 but in agreement with other studies. 13, 16, 20, 23 Published reports [1] [2] [3] [4] [5] 8, 10, 16, 23 recommend maintaining MAP greater than 65 mm Hg to 70 mm Hg to safeguard tissue perfusion in shock. In our study, the MAP was lower in nonsurvivors despite treatment with high-dose norepinephrine, indicating mainly decreased vascular sensitivity, because the 2 outcome groups did not differ in cardiac output. In contrast to MAP, indicators of the severity of shock, such as oliguria, low bicarbonate levels, high lactate levels, and a prolonged prothrombin time, rather than the cause of shock, were more helpful in predicting mortality and in identifying futility. Conversely, oliguria was, not unexpectedly, associated with mortality despite treatment with high-dose norepinephrine, which may benefit renal perfusion and function and reverse renal ischemia if increasing MAP, because the renal vasoconstrictive effects may be only apparent after direct exposure of the kidneys to high doses of the drug (given intraarterially). 13, 15, 16, 20, 21, 23, 28 The high doses of catecholamines used in our patients did not abrogate the high predictive value for mortality of lacticacidemia at admission. This finding is in line with the results of reported studies, even though activation of glycolysis and lacticacidemia by catecholamines may be independent of a shock-induced defect in tissue oxygenation. [1] [2] [3] 5, 10, 23, 24 The elevated prothrombin time may be suggestive of harmful shock-induced diffuse intravascular coagulation despite similar, albeit low, platelet numbers in both outcome groups in our study. The SOFA score at the time of admission was an independent predictor for 28-day mortality, as described before, 14 but did not allow us to define futility (Figure 1 ). In contrast, Abid et al 19 reported a mortality of 100% in shock patients in whom norepinephrine was started (as secondary agent) more than 24 hours after admission and who had a SOFA score greater than 12. Multiorgan failure per se was thus not a predictor of uniform fatality in our patients given high-dose norepinephrine treatment.
infer that relatively high doses (>0.5 µg/kg per minute) increase mortality, but we could not identify a threshold of norepinephrine treatment associated with 100% mortality in our study. We found that the time from the start of norepinephrine treatment to the time of the highest dose was shorter in survivors than in nonsurvivors, and this finding may indicate a beneficial effect of early treatment in attempts to restore MAP. This result also agrees with the findings of Abid et al, 19 even though those authors used norepinephrine as a secondary agent in the treatment of shock, but contrasts with the findings of Subramanian et al, 20 who could not identify a benefit of liberal, that is, early, use of vasopressors in septic shock. Otherwise, the interval between admission and time of highest dose did not independently contribute to the prediction of outcome in multivariable models. In contrast to treatment with norepinephrine alone, concurrent treatment with epinephrine was associated with a worse outcome above the threshold identified, suggesting the futility of epinephrine Norepinephrine dose itself was not a predictor of 28-day mortality. The multivariable analysis of risk factors for mortality may resemble that described for shock. 2, 13, 15, 21 Although our models help show that the underlying disease, the cause of shock, and norepinephrine treatment do not contribute to prediction of mortality, all of the models indicate the importance of the severity of shock (not reflected by MAP) in this regard. However, the models did not substantially improve prediction over that indicated by single variables and did not help in identifying futility, for which single variables were superior. Otherwise, futility was better indicated by shock severity than by comorbid conditions or causes of shock. Of these indicators, only the need for epinephrine cotreatment was included in the multivariable models.
This study had certain limitations. It was a retrospective study done in a single center, and causeand-effect relationships are hard to delineate. Our results are confounded by advanced directives. Treatment withdrawal, when death was conceived as unavoidable by attending physicians, was uniformly associated with death, and our study was intended to objectively derive criteria of futility for future use at the bedside, but not known or used at the time of decision making. The information our results add is an evaluation of the real life on the ICU for a larger population of patients than that evaluated in studies by other investigators, 17, 18 even though the criteria for selecting patients were relatively arbitrary. Finally, no standard method is available for defining and reporting futility, but we evaluated statistically significant thresholds in more than 100 patients, as recommended. 17, 29 In conclusion, high 28-day mortality of critically ill patients with shock who received high-dose norepinephrine in the ICU does not seem to be associated with underlying disease and comorbid conditions, the cause of shock, or dose or duration of norepinephrine treatment. However, our data suggest that treatment with norepinephrine is futile in patients with high disease severity, metabolic acidemia, and need for cotreatment with high doses of epinephrine. Our results may be helpful in future end-of-life decisions, at least in our ICU.
